Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 May;31(5):752–757. doi: 10.1128/aac.31.5.752

Use of recombinant bovine alpha 1 interferon in reducing respiratory disease induced by bovine herpesvirus type 1.

L A Babiuk, M J Lawman, G A Gifford
PMCID: PMC174827  PMID: 3038008

Abstract

Intranasal or intramuscular treatment of calves with recombinant bovine alpha 1 interferon before challenge with bovine herpesvirus type 1 and Pasteurella haemolytica reduced clinical signs, number of sick days, lung lesions, and weight loss. The effective dose was determined to be relatively broad within the range of 1 to 50 mg per animal. No adverse effects were observed even at high doses of interferon (50 mg per animal). Administration before virus infection was more effective than administration at the same time as virus infection. Although interferon administration had dramatic effects on the survival of animals, it did not have much effect on virus secretion in the upper respiratory tract. Therefore, the mechanism by which interferon reduces the susceptibility of animals to viral-bacterial synergy was postulated to be via its immunomodulatory effects.

Full text

PDF
752

Images in this article

754Image
on p.754

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Babiuk L. A., Ohmann H. B., Gifford G., Czarniecki C. W., Scialli V. T., Hamilton E. B. Effect of bovine alpha 1 interferon on bovine herpesvirus type 1-induced respiratory disease. J Gen Virol. 1985 Nov;66(Pt 11):2383–2394. doi: 10.1099/0022-1317-66-11-2383. [DOI] [PubMed] [Google Scholar]
  2. Babiuk L. A., Rouse B. T. Immune interferon production by lymphoid cells: role in the inhibition of herpesviruses. Infect Immun. 1976 Jun;13(6):1567–1578. doi: 10.1128/iai.13.6.1567-1578.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Babiuk L. A., Wardley R. C., Rouse B. T. Defense mechanisms against bovine herpesvirus: relationship of virus-host cell events to susceptibility to antibody-complement cell lysis. Infect Immun. 1975 Nov;12(5):958–963. doi: 10.1128/iai.12.5.958-963.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bielefeldt Ohmann H., Babiuk L. A. Viral-bacterial pneumonia in calves: effect of bovine herpesvirus-1 on immunologic functions. J Infect Dis. 1985 May;151(5):937–947. doi: 10.1093/infdis/151.5.937. [DOI] [PubMed] [Google Scholar]
  5. Brunda M. J., Rosenbaum D. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res. 1984 Feb;44(2):597–601. [PubMed] [Google Scholar]
  6. Cummins J. M., Rosenquist B. D. Protection of calves against rhinovirus infection by nasal secretion interferon induced by infectious bovine rhinotracheitis virus. Am J Vet Res. 1980 Feb;41(2):161–165. [PubMed] [Google Scholar]
  7. Czarniecki C. W., Hamilton E. B., Fennie C. W., Wolf R. L. In vitro biological activities of Escherichia coli-derived bovine interferons-alpha, -beta, and -gamma. J Interferon Res. 1986 Feb;6(1):29–37. doi: 10.1089/jir.1986.6.29. [DOI] [PubMed] [Google Scholar]
  8. De Maeyer E., De Maeyer-Guignard J. Immuno-modulating properties of interferons. Philos Trans R Soc Lond B Biol Sci. 1982 Sep 24;299(1094):77–90. doi: 10.1098/rstb.1982.0108. [DOI] [PubMed] [Google Scholar]
  9. Douglas R. M., Moore B. W., Miles H. B., Davies L. M., Graham N. M., Ryan P., Worswick D. A., Albrecht J. K. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med. 1986 Jan 9;314(2):65–70. doi: 10.1056/NEJM198601093140201. [DOI] [PubMed] [Google Scholar]
  10. Dziewanowska Z. E., Pestka S. The human interferons. Med Res Rev. 1982 Oct-Dec;2(4):325–353. doi: 10.1002/med.2610020403. [DOI] [PubMed] [Google Scholar]
  11. Gresser I. On the varied biologic effects of interferon. Cell Immunol. 1977 Dec;34(2):406–415. doi: 10.1016/0008-8749(77)90262-3. [DOI] [PubMed] [Google Scholar]
  12. Gresser I., Tovey M. G., Maury C., Bandu M. T. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. J Exp Med. 1976 Nov 2;144(5):1316–1323. doi: 10.1084/jem.144.5.1316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hayden F. G., Albrecht J. K., Kaiser D. L., Gwaltney J. M., Jr Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med. 1986 Jan 9;314(2):71–75. doi: 10.1056/NEJM198601093140202. [DOI] [PubMed] [Google Scholar]
  14. Herberman R. B., Ortaldo J. R., Mantovani A., Hobbs D. S., Kung H. F., Pestka S. Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol. 1982 Feb;67(1):160–167. doi: 10.1016/0008-8749(82)90208-8. [DOI] [PubMed] [Google Scholar]
  15. Jakab G. J. Immune impairment of alveolar macrophage phagocytosis during influenza virus pneumonia. Am Rev Respir Dis. 1982 Nov;126(5):778–782. doi: 10.1164/arrd.1982.126.5.778. [DOI] [PubMed] [Google Scholar]
  16. Johnson H. M., Smith B. G., Baron S. Inhibition of the primary in vitro antibody response by interferon preparations. J Immunol. 1975 Jan;114(1 Pt 2):403–409. [PubMed] [Google Scholar]
  17. Markham R. J., Ramnaraine M. L., Muscoplat C. C. Cytotoxic effect of Pasteurella haemolytica on bovine polymorphonuclear leukocytes and impaired production of chemotactic factors by Pasteurella haemolytica-infected alveolar macrophages. Am J Vet Res. 1982 Feb;43(2):285–288. [PubMed] [Google Scholar]
  18. Merigan T. C., Rand K. H., Pollard R. B., Abdallah P. S., Jordan G. W., Fried R. P. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med. 1978 May 4;298(18):981–987. doi: 10.1056/NEJM197805042981801. [DOI] [PubMed] [Google Scholar]
  19. Merigan T. C., Reed S. E., Hall T. S., Tyrrell D. A. Inhibition of respiratory virus infection by locally applied interferon. Lancet. 1973 Mar 17;1(7803):563–567. doi: 10.1016/s0140-6736(73)90714-9. [DOI] [PubMed] [Google Scholar]
  20. Nakamura M., Manser T., Pearson G. D., Daley M. J., Gefter M. L. Effect of IFN-gamma on the immune response in vivo and on gene expression in vitro. 1984 Jan 26-Feb 1Nature. 307(5949):381–382. doi: 10.1038/307381a0. [DOI] [PubMed] [Google Scholar]
  21. Ohmann H. B., Babiuk L. A. Effect of bovine recombinant alpha-1 interferon on inflammatory responses of bovine phagocytes. J Interferon Res. 1984 Spring;4(2):249–263. doi: 10.1089/jir.1984.4.249. [DOI] [PubMed] [Google Scholar]
  22. Ohmann H. B., Babiuk L. A. In vitro and systemic effects of recombinant bovine interferons on natural cell-mediated cytotoxicity in healthy and bovine herpesvirus-1-infected cattle. J Interferon Res. 1985 Fall;5(4):551–564. doi: 10.1089/jir.1985.5.551. [DOI] [PubMed] [Google Scholar]
  23. Ohmann H. B., Gilchrist J. E., Babiuk L. A. Effect of recombinant DNA-produced bovine interferon alpha (BoIFN-alpha 1) on the interaction between bovine alveolar macrophages and bovine herpesvirus type 1. J Gen Virol. 1984 Sep;65(Pt 9):1487–1495. doi: 10.1099/0022-1317-65-9-1487. [DOI] [PubMed] [Google Scholar]
  24. Sehgal P. B. The interferon genes. Biochim Biophys Acta. 1982 Sep 30;695(1):17–33. doi: 10.1016/0304-419x(82)90004-x. [DOI] [PubMed] [Google Scholar]
  25. Senik A., Gresser I., Maury C., Gidlund M., Orn A., Wigzell H. Enhancement by interferon of natural killer cell activity in mice. Cell Immunol. 1979 Apr;44(1):186–200. doi: 10.1016/0008-8749(79)90039-x. [DOI] [PubMed] [Google Scholar]
  26. Shalaby M. R., Weck P. K., Rinderknecht E., Harkins R. N., Frane J. W., Ross M. J. Effects of bacteria-produced human alpha, beta, and gamma interferons on in vitro immune functions. Cell Immunol. 1984 Apr 1;84(2):380–392. doi: 10.1016/0008-8749(84)90110-2. [DOI] [PubMed] [Google Scholar]
  27. Thomson R. G., Chander S., Savan M., Fox M. L. Investigation of factors of probable significance in the pathogenesis of pneumonic pasteurellosis in cattle. Can J Comp Med. 1975 Apr;39(2):194–207. [PMC free article] [PubMed] [Google Scholar]
  28. Todd J. D., Volenec F. J., Paton I. M. Interferon in nasal secretions and sera of calves after intranasal administration of avirulent infectious bovine rhinotracheitis virus: association of interferon in nasal secretions with early resistance to challenge with virulent virus. Infect Immun. 1972 May;5(5):699–706. doi: 10.1128/iai.5.5.699-706.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Velan B., Cohen S., Grosfeld H., Leitner M., Shafferman A. Bovine interferon alpha genes. Structure and expression. J Biol Chem. 1985 May 10;260(9):5498–5504. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES